chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I first had little pin prick pains on different areas of body. Maybe 4 or 5 a day. In about 2 weeks chronic prickling, tingling, burning and some stabbing pain started. This has been on going now ever since. Some days a better than others. This is a very uncomfortable feeling.  I think it has gotten better. Today isn't a good day. This has been going on for over 4 months. I am taking Doxepin 2 10 milligram capsules.
Only received 1st round dosage of COVID vaccination, he seemed to handle vaccination okay.   On January 17, 2021, he tested COVID positive on a resident screening test done in response to an employee positive case in days previous to the residents testing.  Fifteen days after his first innoculation,his AM nurse found him non-responsive on early vital checks.  Vitals at that time were normal range.  The facility physician was contacted and advised that he should be taken to Emergency Room at local hospital for further evaluation.  Blood work was taken and ER DR diagnosed Heart enzymes elevated indicating a heart attack.  Advised additional testing should be done, and that monoclonal antibody treatment wasn't an option due to time lapse since diagnosis of  COVID,  The option of comfort care was chosen as the treatment plan.
Vaccine went into 2-8 Celsius thaw state on or about 24 Dec 2021 and administered on 28 Jan 2022; Vaccine went into 2-8 Celsius thaw state on or about 24 Dec 2021 and administered on 28 Jan 2022; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24 Dec 2021 and administered on 28 Jan 2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24 Dec 2021 and administered on 28 Jan 2022) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2022 at 2:29 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 28-Jan-2022 at 2:29 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24 Dec 2021 and administered on 28 Jan 2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24 Dec 2021 and administered on 28 Jan 2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24 Dec 2021 and administered on 28 Jan 2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24 Dec 2021 and administered on 28 Jan 2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.    It was unknown if the patient received any prescriptions, over the counter medications, dietary supplements or herbal remedies at the time of vaccination. It was unknown if the patient received other vaccines given on the same day and it was also unknown if the patient received other vaccines within one month prior to Moderna vaccine. The patient received booster dose and vaccination time reported as at 14.29.38. It was reported that, the vaccines went in to 2-8  Celsius  thaw state on or about 24 Dec 2021.This vaccine was administered up until its manufacturing expiry date of 04 Apr 2022. It was unknown if the patient experienced any adverse events or not. No treatment medications were reported.   This case was linked to MOD-2022-542869 (Patient Link).
Covid test result=Positive; Covid test result=Positive; This is a spontaneous report received from a non-contactable reporter(s) (Nurse).  A 40-year-old female patient received BNT162b2 (BNT162B2), on 29Mar2021 as dose 1, single (Batch/Lot number: unknown), on 17Apr2021 as dose 2, single (Batch/Lot number: unknown) and on 03Dec2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 40 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 17Jul2022, outcome "unknown" and all described as "Covid test result=Positive". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (17Jul2022) Positive, notes: covid test type post vaccination: Nasal Swab. Clinical information: Patient experienced moderate fever and sinus congestion. Prior to vaccination patient was not diagnosed with COVID-19.    No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on available information , there is reasonable possibility of causal association between the events Vaccination Failure and COVID 19 and the suspect drug BNT162b2 .
Sudden total hearing loss in left ear; This spontaneous case was received on 05-Nov-2021 from other non-health professional (consumer) via Pfizer (reference number: 202101440993) with additional information (being processed together) received on the same communication (reference number: SEQW21-05120) and concerned a 49-year-old male patient.  The patient's concurrent condition included codeine allergy. The patient's concomitant medications included omeprazole for unknown indication. The patient's previously received two doses of Pfizer BioNTech COVID-19 vaccine after which the patient did not developed any adverse event.  On 15-Oct-2021, the patient was vaccinated with Afluria Quadrivalent (influenza vaccine; anatomical location: right arm, dose, route of administration and indication: not reported). The batch number was not reported.  On the same day, the patient was vaccinated with non-company co-suspect Pfizer BioNTech COVID-19 vaccine (tozinameran; anatomical location: left arm, route of administration, dose, batch number and indication: not reported).  On 23-Oct-2021, eight days after administration of Afluria Quadrivalent and Pfizer BioNTech COVID-19 vaccine, the patient experienced sudden total hearing loss in left ear. The patient was treated with high dose of steroids.   At the time of initial report on 05-Nov-2021, the patient had not recovered from the event.  The reporter did not provide a causality assessment.  The event of 'hearing loss' was assessed as serious due to disability and was also considered to be medically significant by a Physician from facilitating company.  Company comment: A 49-year-old, male patient was vaccinated with the suspect Afluria Quadrivalent and non-company co-suspect Pfizer BioNTech COVID-19 vaccine. Eight days after vaccination the patient developed sudden total hearing loss in left ear. Information regarding the related diagnostic findings has not been provided. Due to limited information provided, causality is unassessable.; Sender's Comments: A 49-year-old, male patient was vaccinated with the suspect Afluria Quadrivalent and non-company co-suspect Pfizer BioNTech COVID-19 vaccine. Eight days after vaccination the patient developed sudden total hearing loss in left ear. Information regarding the related diagnostic findings has not been provided. Due to limited information provided, causality is unassessable.
Hello, I am an adult in good health. Before my vacation traveling started, I was advised to take the typhoid vaccine. My doctor prescribed the VIVOTIF EC Cap (one pill every other day four times in total). After initiating the first capsule, I developed abdominal pain followed by diarrhea. I finished the treatment as prescribed. However the following week, I experienced terrible aching, swollen and stiff pain in my hand joints which I had never experienced before. I reported this to my doctor and she wanted to wait and see. By 16Sep2018 before my vacation began, the aching had spread all over my body joints given me the feeling of having a flu but it was not a flu. I contacted my doctor again because walking was very painful and by this time I stopped going to the gym. I couldn't run or do weight lifting that I normally do. I was very perplexed because my diet and routines were not altered in any way. The only change was the administration of this vaccine the week prior before the onset of these symptoms. My doctor (Internist) suggested that I take ADVIL during my vacation to manage the ache/pain and stiffness. I took the ADVIL and then stopped since it didn't alleviate the pain/ache and the stiffness. It was very hard to do physical activities while I was on vacation. I had to move very slowly and it ached a lot when walking up and down the stairs or whenever joint movements were required, even putting clothes on/off. I still have this problem to this day. It has not subsided over time as I had hoped. I will make an appointment to see my doctor or referred specialist to perform some tests to determine the problem. I still have the package of this vaccine that I took.
Vaccine given at 1640 in LD by CMA. Patient began to feel light-headed about 5 minutes after injection in the lobby. On-site provider was informed and came to lobby to assess patient. BP: 105/77, O2: 98%, HR: 100bpm. Mother informed provider this had also happened with previous first dose of covid vaccine.  Patient reported that she had not eaten much during the day and was offered a granola bar and juice. Patient drank juice and began feeling better towards the end of her 15 minute observation period. Provider determined patient could leave and reviewed emergent signs with mother. No further medical attention or follow-up needed.
Patient  presented to the emergency center with abdominal pain, dizziness, and shortness of breath for 3 days. Stated had surgery for hernia a week earlier and feared a surgical infection. However he tested positive for COVID.
Systemic: Confusion-Mild, Systemic: Dizziness / Lightheadness-Medium, Systemic: LEFT ARM TREMERS-Mild, Systemic: Nausea-Mild
rash; headache; weakness; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (weakness), VACCINATION SITE RASH (rash) and HEADACHE (headache) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 180B2A) for COVID-19 vaccination.     No medical history was provided.     On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, the patient experienced ASTHENIA (weakness). On 03-Apr-2021, the patient experienced HEADACHE (headache). On 14-Apr-2021, the patient experienced VACCINATION SITE RASH (rash). At the time of the report, ASTHENIA (weakness) had resolved and VACCINATION SITE RASH (rash) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Headache, Myalgia, Arthralgia, NauseaVomiting, sore throat Narrative:  Other Relevant History:
Bad nose with shingles; Bad nose with shingles; This is a spontaneous report from a contactable consumer (patient) or other non health care professional.  A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), dose 2 via an unspecified route of administration in 2021 as DOSE 2, SINGLE for covid-19 immunisation. Medical history included ongoing diabetes mellitus. The patient's concomitant medications were not reported. The patient experienced bad nose with shingles in 2021. She was calling because she said she had the first dose of the shot in April and she started having pain and she said she was the diabetic (Intent of medical history) and she said ever since she got the shot she can't do the insulin injection (Further clarification unknown hence captured suspect as Unspecified medication) all because it was hurting and burning so bad but she said after she got the second shot she was started feeling better but she was still can't do her injections because she said it hurts and feels so bad and she has recently bad nose with shingles and she says she had believes that it is because of the Covid vaccine and she was calling to report those events. The outcome of the events was unknown. Information about lot/batch number has been requested.
The patient presented with myalgias and chest pain. He was found to have myopericarditis.
Jynneos vaccine was thawed longer than 8 weeks; Affected Jynneos vaccine was administrated; Case reference number US-BN-2022-003961 is a spontaneous case report initially received on 05-Oct-2022 from nurse via Communications (reference number: USBAV22-1628) and concerns a patient of unknown demographics (sixth out of ten).  The patient's medical history and concomitant medication details were not provided.  On 3-Oct-2022 and 4-Oct-2022, the patient was vaccinated with Jynneos vaccine (Smallpox and Monkeypox Vaccine, Live, Nonreplicating; batch number unknown) at an unknown dose, route and site of administration for monkeypox/smallpox prophylaxis. Jynneos vaccine was thawed longer than eight weeks before administration (explicitly coded as 'product storage error' and product administration error').  At the time of this report, it was unknown if the patient experienced any adverse events.  Additional information received on 05-Oct-2022 from a nurse via Communications (reference number: USBAV22-1630): new information included clarification regarding number of patients involved.  The case is linked to the cases US-BN-2022-003913, US-BN-2022-003956, US-BN-2022-003958, US-BN-2022-003959, US-BN-2022-003960, US-BN-2022-003962, US-BN-2022-003963, US-BN-2022-003964 and US-BN-2022-003965, due to same reporter.; Reporter's Comments: A patient of unknown demographics was vaccinated for monkeypox/smallpox prophylaxis with Jynneos vaccine that was thawed longer than eight weeks before administration, which is considered as product storage error and product administration error. Product storage error and product administration error are considered listed per company convention. At the time of this report, it was unknown if the patient experienced adverse events. The patient's medical history and concomitant medication details were not provided. Product storage error and product administration error have been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown demographics was vaccinated for monkeypox/smallpox prophylaxis with Jynneos vaccine that was thawed longer than eight weeks before administration, which is considered as product storage error and product administration error. Product storage error and product administration error are considered listed per company convention. At the time of this report, it was unknown if the patient experienced adverse events. The patient's medical history and concomitant medication details were not provided. Product storage error and product administration error have been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
In order of onset: soreness at shot location; headache, came in waves moderate to severe; joint pain in ALL major  joints; chills; muscle weakness  and fatigue.  Symptoms began the evening of receiving shot and worsening  throughout the next day.  I did not take medication  for the headaches. I slept longer than normal for the two days post shot (4 hours  each day). Stayed hydrated and limited physical activity.
Fever; Chills; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) and CHILLS (Chills) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) Booster dose. In October 2021, the patient experienced PYREXIA (Fever) and CHILLS (Chills). At the time of the report, PYREXIA (Fever) and CHILLS (Chills) outcome was unknown.       No Concomitant medication details were provided. No Treatment medication details were provided.  Caller did mention one or two other AE, but agent unable to capture. Caller declined to report /disclose additional AE information.   Reporter did not allow further contact
Hives and or Shingles, short of breath, fatigue, anxiety, loss of appetite and lethargic with a rapid heart beat and nausea car sick like feeling. Slight chest discomfort.
Received stem cell transplant after 1st dose; This case was reported by a pharmacist via call center representative and described the occurrence of stem cell transplant in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced stem cell transplant. On an unknown date, the outcome of the stem cell transplant was unknown.   It was unknown if the reporter considered the stem cell transplant to be related to Shingrix.     Additional Information: GSK receipt date: 26-Jul-2022 Reporters comment: The patient received stem cell transplant after receiving dose of Shingrix. The reporter consent to follow-up.
Large, round, red, raised, warm, itchy and tender area at injection site 22 days post injection. Stiff neck and runny nose.
Swollen/hot to touch/red/pain at sure if injection.  Next day redness moved down arm to elbow . Pain increased /swollen lump /hot to touch.
Local reaction with warmth, erythema and tenderness around injection sites of VARIVAX, ADACEL, and MENACTRA in both arms
pt recv vax 16SEP96-fever to 104 later that evening while taking Ibuprofen mom called MD;fever cont high thru 18SEP96 peaking @ 106.9;mom gave both APAP & Ibuprofen;pt fussy, pale, not as alert as usual;mom called MD;19SEP96 fever lower;
6-8 hours after receiving vaccination body began twitching, began to subside after a couple of hours. Twitching has reoccurred.
Patient was given Pfizer 5-11 instead of finishing primary series with 6 month to 4 year
HYPOTENSION 10/4/2021 DM 2 W ULCER OF RIGHT FOOT  ACUTE RESPIRATORY FAILURE 12/27/2021 DM 2 W ULCER OF RIGHT FOOT  HYPOTENSION 10/4/2021 AFTERCARE FOR CIRCULATORY SYSTEM SURGERY  ACUTE RESPIRATORY FAILURE 12/27/2021 AFTERCARE FOR CIRCULATORY SYSTEM SURGERY  HYPOTENSION 10/4/2021 RIGHT FOOT CELLULITIS  ACUTE RESPIRATORY FAILURE 12/27/2021 RIGHT FOOT CELLULITIS  HYPOTENSION 10/4/2021 ATRIAL FLUTTER, UNSPECIFIED  ACUTE RESPIRATORY FAILURE 12/27/2021 ATRIAL FLUTTER, UNSPECIFIED
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 40-year-old male patient received BNT162b2 (BNT162B2), on 26Feb2021 as dose 1, single (Lot number: EL9266), in left arm, on 19Mar2021 as dose 2, single (Lot number: EN6205), in left arm and on 28Sep2021 as dose 3 (booster), single (Lot number: FF8839) at the age of 39 years for Covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 21Apr2022, outcome "not recovered" and all described as "I tested positive for Covid-19 on 21Apr". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) negative, notes: After taking the full course of Paxlovid I tested negative for 1 day; (unspecified date) Positive, notes: tested positive again and remain positive; (21Apr2022) Positive. Therapeutic measures were taken as a result of vaccination failure, Covid-19. Clinical course: Patient received vaccine. He did not receive any other medication in 2 weeks. Paxlovid (lot number=FX8140) was given as a treatment for Covid-19 on 21Apr2022 and stopped on 27Apr2022. He tested positive for Covid-19 on 21Apr. After taking the full course of Paxlovid he tested negative for 1 day and then tested positive again and remain positive. On day ten patient started having symptoms, mainly in the evening, and now lethargy, runny nose, and a slight cough are back again. Adverse event started on 01May2022. No treatment was given for this. Patient had no known allergies. No follow up attempts are possible. No further information is expected.
pt was exposed to sibling who recv vax WAES97060538 & mom WAES97061274 who contracted varicella via secondary trans & 26MAY97 pt devel full blown case of varicella;
thrombus in my left foot; my leg swelled up; This spontaneous case was reported by a consumer and describes the occurrence of THROMBOSIS (thrombus in my left foot) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Factor V deficiency and Anticoagulant therapy.    On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced THROMBOSIS (thrombus in my left foot) (seriousness criterion medically significant) and PERIPHERAL SWELLING (my leg swelled up). At the time of the report, THROMBOSIS (thrombus in my left foot) had resolved and PERIPHERAL SWELLING (my leg swelled up) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication included Blood Thinners. No Treatment medication details was provided. It was reported that The thrombus disappeared after 2 days.  Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  Further information has been requested; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  Further information has been requested
Missed second dose; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed second dose) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed second dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed second dose) had resolved.            No concomitant medications were reported.  It was reported that the patient's wife said her husband received the second shot on 12-Apr-2021 but had no reaction with any of the doses, so she denied any further follow up.  No treatment information was provided.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 16-Jun-2021: Follow up received on 16-Jun-2021 and included information about second dose.; Sender's Comments: This report refers to a case of Product administration error for mRNA-1273, lot # unknown  with no associated AEs.